ACTC1 and prostate carcinoma: ACTC1 has been shown to predict metastasis-free survival in patients undergoing radical radiotherapy for prostate cancer [33], and its expression is upregulated in the skeletal muscles of men with prostate cancer receiving androgen deprivation therapy, potentially representing a compensatory response to therapy-induced muscle loss [34].